The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Advances in Lung, Testicular Cancer


EMBARGOED FOR RELEASE UNTIL EARLIER OF:
START OF PRESS BRIEFING OR START OF SCIENTIFIC SESSION

See attached summaries for exact times

CONTACT:
Annual Meeting News Room
312-949-3200

ASCO Media Information Line
212-584-5010

-- PRESS BRIEFING SUNDAY, JUNE 1, 9:00 AM (CDT) --

-- Cetuximab with Chemotherapy Improves Survival in Patients with Advanced Non-Small Cell Lung Cancer; Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer --

Chicago, IL—Two plenary studies and other research evaluating screening and treatment options for patients with lung and testicular cancer were released today at a press briefing for the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).

“These findings are likely to have a significant impact on the care of patients with these types of cancer,” said Howard Sandler, MD, professor in the departments of radiation oncology and urology at the University of Michigan and moderator of the press briefing. “Our goal as physicians and researchers is to catch cancer early, improve survival and enhance quality of life. These studies advance all those aims.”

Plenary studies include:

  •  A study finding that the targeted therapy cetuximab (Erbitux) combined with platinum-based chemotherapy is effective as a first-line treatment for patients with advanced non-small cell lung cancer.

  •  A study showing that a single dose of carboplatin chemotherapy is as effective and less toxic than radiation therapy in preventing recurrence after surgery for early-stage testicular cancer. Testicular cancer is the most common form of cancer in younger men, with 8,000 cases annually.

The press briefing also highlighted other studies on cancer prevention and diagnosis:

  •  A study evaluating whether celecoxib (Celebrex, a COX-2 inhibitor) is a potential chemopreventive agent for lung cancer in current and former smokers. VIEW SUMMARY

  • A study assessing whether PET/CT is superior to standard CT for staging disease in patients with lung cancer. Accurate cancer staging is critical to determining whether patients will benefit from surgery. VIEW SUMMARY

For consumer-oriented information on these studies and more than 120 cancer types and cancer-related syndromes, please refer your readers to ASCO’s oncologist-vetted patient website, www.cancer.net.

VIEW FULL PRESS RELEASE





 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2011 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.
Feedback Form